Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma.
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma.
复制标题
靶向治疗的基本原理以及帕唑帕尼在晚期肾细胞癌中的潜在作用。
DOI：
10.2147/btt.s7818
复制
发表时间：
2010-08-09
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
晚期肾细胞癌（RCC）仍然是一个具有挑战性的主要健康问题。最近在了解一种形式的RCC（即透明细胞（或常规）RCC）的基础生物学方面的进展为一系列靶向药物（如酪氨酸激酶抑制剂（TKI））打开了大门，这些药物已成为管理晚期透明细胞RCC的标准治疗。在这些药物中，最新获得食品和药物管理局批准用于这种疾病的是帕唑帕尼。本综述将总结透明细胞肾细胞癌的基础生物学知识，围绕先前批准的针对这种疾病的靶向药物的数据，不仅包括TKI，还包括mTOR抑制剂和血管内皮生长因子特异性药物贝伐单抗，以及最新的TKI，帕唑帕尼。它还将探索帕唑帕尼相对于其他可用药物的潜在作用，以及它可能适合治疗晚期/转移性RCC的医疗设备。
Advanced renal cell carcinoma (RCC) remains a challenging, major health problem. Recent advances in understanding the fundamental biology underlying one form of RCC, ie, clear cell (or conventional) RCC, have opened the door to a series of targeted agents, such as the tyrosine kinase inhibitors (TKIs), which have become the standard of care in managing advanced clear cell RCC. Among the newest of these agents to receive Food and Drug Administration approval in this disease is pazopanib. This review will summarize what is known about the fundamental biology that underlies clear cell RCC, the data surrounding the previously approved targeted agents for this disease, including not only the TKIs but also the mTOR inhibitors and the vascular endothelial growth factor-specific agent, bevacizumab, and the newest TKI, pazopanib. It will also explore the potential role for pazopanib relative to the other available agents and where it may fit into the armamentarium for treatment of advanced/metastatic RCC.